Does ferroptosis play a key role in cardiovascular diseases?

Cardiovascular diseases remain the leading cause of mortality worldwide, affecting millions of people each year. A recent discovery has shed light on a still little-known biological mechanism that could revolutionize the understanding and treatment of these conditions: ferroptosis. This regulated cell death process, triggered by excessive iron accumulation and lipid peroxidation, appears to play a central role in the progression of many cardiovascular diseases, such as atherosclerosis, myocardial infarction, heart failure, and hypertension.

Ferroptosis differs from other forms of cell death due to its dependence on iron and free radicals. Iron, while essential for many biological functions, can become toxic if it accumulates in excess within cells. Through chemical reactions, it generates free radicals that attack the lipids in cell membranes, causing their peroxidation. This phenomenon disrupts cell integrity and leads to cell death. In the heart and blood vessels, where cells are particularly rich in polyunsaturated lipids, this vulnerability is even more pronounced.

Research shows that ferroptosis is involved in several pathological processes. For example, in atherosclerosis, iron accumulation in arterial plaques promotes their instability and rupture, leading to serious complications such as heart attacks. During a myocardial infarction, the reoxygenation of cardiac tissue after ischemia can trigger massive ferroptosis, worsening cellular damage. Similarly, in heart failure, excess iron and free radicals disrupt mitochondrial function, which is essential for energy production in cardiac cells.

Ferroptosis is also linked to inflammation, a key mechanism in cardiovascular diseases. Cells dying by ferroptosis release signals that activate the immune system, creating a vicious cycle where inflammation worsens ferroptosis, and vice versa. This interaction is particularly evident in conditions such as hypertension, where oxidative stress and iron accumulation in blood vessels contribute to their stiffness and dysfunction.

In light of these findings, researchers are exploring new therapeutic strategies to specifically target ferroptosis. Molecules capable of chelating iron—that is, binding it to reduce its accumulation—or antioxidants that neutralize free radicals show promising results in experimental models. For instance, inhibitors of lipid peroxidation or activators of natural antioxidant pathways, such as the GPX4 pathway, could protect cardiac cells from ferroptosis-related damage.

However, translating these discoveries into clinical applications remains a challenge. The exact mechanisms of ferroptosis in the human body are not yet fully understood, and reliable biomarkers are lacking to identify patients who could benefit from these new treatments. Additionally, current therapies need to be optimized to avoid undesirable side effects, such as disruption of the body’s natural iron balance.

Despite these obstacles, ferroptosis represents a promising avenue for the development of more targeted and effective treatments against cardiovascular diseases. By better understanding how this process contributes to the degradation of cardiac and vascular tissues, scientists hope to pave the way for innovative therapies capable of reducing the global burden of these devastating diseases.

Legal Attributions

Study Citation

DOI: https://doi.org/10.1186/s43556-026-00420-9

Title: Ferroptosis in cardiovascular diseases: molecular mechanisms and a novel therapeutic target

Journal: Molecular Biomedicine

Publisher: Springer Science and Business Media LLC

Authors: Suli Yu; Zhen Pang; Hong Fang; Chi Liu